| Filed On | Filing |
|---|---|
| 16 Oct 2024 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. |
| 23 Feb 2023 |
8-K/A: Results of Operations and Financial Condition
Phase 1 Dose Escalation Data from the Ongoing Phase 1/2 Clinical Trials of CFT7455, an IKZF1/3 MonoDAC™ Degrader, and CFT8634, a BRD9 BiDAC™ Degrader, Expected in 2H 2023 |
| 22 Sep 2022 |
8-K/A: Submission of Matters to a Vote of Security Holders
As previously reported in the Original Form 8-K, the Company’s stockholders cast a majority of votes in favor of recommending a frequency of one year for future executive compensation advisory votes, through an advisory, non-binding reso... |
| 21 Jan 2022 | 8-K/A: Financial Statements and Exhibits |
Loading...
